Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Completed

Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer

A Non-controlled, Single Arm, Open Label, Phase II Study of Intravenous and Intratumoral Administration of ParvOryx in Patients With Metastatic, Inoperable Pancreatic Cancer

NCT02653313↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome
Finished, no results posted
Phase
Phase 1 / Phase 2
Status
Completed
Study type
Interventional
Start
December 2015
Expected end
May 2018
Enrollment
7 participants
Sites
1
Primary outcomes
Safety and tolerability of the IMP; Safety and tolerability of the IMP; Safety and tolerability of the IMP; Safety and tolerability of the IMP; Humoral immuneresponse to the IMP
Sponsor
Industry
Results posted
No
Last update
21 November 2022

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Investigation on safety, tolerability and efficacy of parvovirus H-1 (ParvOryx) in subjects suffering from metastatic, inoperable pancreatic cancer with at least one hepatic metastasis.

Detailed description public domain (ClinicalTrials.gov)

Investigation on safety, tolerability and efficacy of parvovirus H-1 (ParvOryx) in subjects suffering from metastatic, inoperable pancreatic cancer with at least one hepatic metastasis. Initially four equal doses of ParvOryx will be administered intravenously on four consecutive days. Seven to fourteen days after the first intravenous administration the drug will be injected directly in a hepatic metastasis of the pancreatic cancer.

Papers 2